Cullinan Sends Two T Cell Engagers to ASH 2026

Cullinan Therapeutics (Nasdaq: CGEM) said on 4 November 2026 that four poster presentations covering its CLN-049 and velinotamig T cell engager programs will be featured at the 68th American Society of Hematology Annual Meeting, held 12-15 December 2026 in New Orleans. The company said the CLN-049 Phase 1 dose escalation abstract reports anti-leukemic activity at selected Phase 2 target doses of 6 micrograms per kilogram and 12 micrograms per kilogram, plus a favorable safety profile for the double step-up dosing regimen.

Context — why two T cell engager posters matter now

Cullinan is a clinical-stage biopharmaceutical company developing what it describes as potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer. The ASH slate is the company's own framing of where its pipeline stands: one asset in relapsed disease, one moving into frontline combination, and one crossing from oncology into autoimmune cytopenias.

The report gives no prior-period efficacy figures, so the magnitude of the anti-leukemic activity update cannot be measured against an earlier readout. What the company does disclose is that updated dose escalation results for the selected Phase 2 regimens will be detailed further in the poster, meaning the abstract understates the data set that will be visible in New Orleans.

CLN-049 already carries two regulatory designations from the U.S. FDA for relapsed or refractory AML: Orphan Drug designation and Fast Track designation. Those designations are granted on the basis of serious unmet need, and the company's own background notes that no immunotherapies are currently approved for AML.

The macro backdrop is not addressed in the report. No financing terms, cash position, or share count is disclosed, and the company did not provide guidance on either program's timing beyond the December sessions.

Data — the numbers the company disclosed

The concrete figures in the announcement are dosing and scheduling, not efficacy endpoints. CLN-049's selected Phase 2 target doses are 6 micrograms per kilogram and 12 micrograms per kilogram, and the double step-up regimen is described as having a favorable safety profile. The company did not disclose response rates, duration of response, or patient counts.

Program	Session date	Poster number
CLN-049 updated Phase 1 (R/R AML, MDS)	13 December 2026	3385
CLN-049 plus venetoclax/azacitidine, newly diagnosed AML	12 December 2026	1640
Velinotamig preclinical, autoimmune cytopenias	12 December 2026	2384
Velinotamig Phase 1b/2a trial in progress, ITP and wAIHA	13 December 2026	3001

All four posters sit in MCCNO Hall F. The two 12 December sessions run 5:30 p.m. to 7:30 p.m.; the two 13 December sessions run 6:00 p.m. to 8:00 p.m.

The disease-burden figures the company cites give scale to the addressable populations. Approximately 23,000 people are diagnosed with AML each year in the U.S., and about half as many lives are lost to the disease. Globally, AML affects an estimated 145,000 people annually with roughly 130,000 deaths.

For the autoimmune side, U.S. chronic primary ITP prevalence among adults is estimated at 23.6 per 100,000 people, or approximately 62,000 adults. U.S. adult wAIHA prevalence is estimated at approximately 33,300 adults.

Analysis — what the ASH slate signals for CGEM

The structural read is that Cullinan is running one molecule across two very different commercial arenas. CLN-049 targets FLT3-expressing leukemia cells and binds both mutated and non-mutated FLT3, which the company says makes the approach applicable regardless of FLT3 mutational status — a wider label than mutation-selective competitors would carry.

Velinotamig is the more interesting optionality. It is a BCMAxCD3 engager engineered with high-affinity BCMA binding and lower-affinity CD3 binding, a design intended to deplete target cells while limiting non-specific T cell activation and cytokine-related toxicity. Cullinan holds a global, ex-Greater China, all-indication exclusive license from Genrix Bio, and Genrix is running a separate Phase 1b/2a in refractory systemic lupus erythematosus in China.

The counter-argument is timing. All four posters are either updated early-stage data or Trials in Progress, which by definition contain no efficacy readout. Preclinical data on velinotamig targeting BCMA-expressing B-lineage cells supports a mechanism but does not de-risk a Phase 1b/2a. Investors treating the ASH slate as a binary catalyst would be misreading its function.

Positioning follows that distinction. The relapsed/refractory AML five-year survival figure cited by the company is 10% or less, and patients with high-risk features such as complex karyotype or TP53 mutations face especially limited options. That is the unmet-need argument a partner or acquirer would underwrite, and it is the reason a clinical-stage name with no approved product carries strategic value ahead of a data-heavy conference.

Outlook — what to watch next

The first hard catalyst is 12 December 2026, when the CLN-049 combination Trial in Progress and the velinotamig preclinical poster both present in Hall F. The second is 13 December 2026, when the updated Phase 1 CLN-049 dose escalation results — the only poster in the set carrying new clinical activity data — are detailed.

What matters inside those sessions is whether the 6 and 12 microgram per kilogram cohorts show durable anti-leukemic activity alongside the stated safety profile, and whether the double step-up regimen remains tolerable at the higher dose. The company has not disclosed a target enrollment or completion date for either the relapsed/refractory study or the newly diagnosed combination study.

Beyond December, watch for any update on the velinotamig Phase 1b/2a in immune thrombocytopenia and warm autoimmune hemolytic anemia, and for Genrix's separate SLE trial in China. The report names no efficacy thresholds, no response-rate benchmarks, and no share-price levels, so no numeric bar can be set from the disclosure itself.

Frequently Asked Questions

What is CLN-049 and what does the ASH data actually show?

CLN-049 is an investigational FLT3xCD3 T cell engager designed to target FLT3-expressing leukemia cells in AML and MDS. At ASH 2026, the company said its Phase 1 abstract reports anti-leukemic activity at selected Phase 2 target doses of 6 and 12 micrograms per kilogram, with a favorable safety profile for the double step-up regimen. Updated dose escalation results for the selected Phase 2 regimens will be detailed further in the poster session on 13 December 2026.

How does velinotamig differ from Cullinan's cancer programs?

Velinotamig, also called CLN-803, is a BCMAxCD3 T cell engager aimed at autoimmune cytopenias rather than oncology. It is engineered with high-affinity BCMA binding and lower-affinity CD3 binding to deplete pathogenic autoantibody-producing plasma cells while limiting non-specific T cell activation. Cullinan licenses it globally outside Greater China from Genrix Bio, which is separately testing it in refractory lupus in China.

What are the market sizes Cullinan cites for these indications?

The company cites approximately 23,000 U.S. AML diagnoses annually and about 145,000 cases globally, with roughly 130,000 deaths. For the autoimmune programs, it estimates U.S. adult chronic primary ITP prevalence at about 62,000 adults and U.S. adult warm autoimmune hemolytic anemia prevalence at approximately 33,300 adults. Relapsed or refractory AML five-year survival is put at 10% or less.

Bottom Line

Cullinan's ASH slate offers updated early-stage CLN-049 activity data but no efficacy readout for velinotamig.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.